IP Library › Granted Patent US 12,386,204
Granted Patent B2
US 12,386,204 · App. 18/657,667 · Granted Aug 12, 2025

Systems, apparatus, and methods for regulating refractive error development through the modulation of peripheral distortion

Inventors: Jerome A. Legerton (Jupiter Inlet Colony, FL); Jidong Liu (Shenyang, CN); Gaozhi Liu (Shenyang, CN)
Assignee: Shenyang Kangende Medical Science and Technology Co., Ltd.
G02C7/086G02C7/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,386,204
App. No.
18/657,667
Granted
Aug 12, 2025
Kind
B2
Abstract

In general, one aspect disclosed features a spectacle lens, comprising: a central zone having an optical center corresponding to the visual axis of an eye of a patient; and a peripheral zone peripheral to the central zone and comprising: a first zone having a first thickness, and a second zone having a second thickness, wherein: the second thickness varies from the first thickness, and a distance from the second zone to the optical center of the central zone is selected to generate pincushion distortion or barrel distortion in the eye of the patient.

Claims (45)

1. A spectacle lens, comprising:

a central zone having an optical center corresponding to the visual axis of an eye of a patient; and

a peripheral zone peripheral to the central zone and comprising: a first zone having a first thickness, and

a second zone having a second thickness, wherein:

the second thickness varies from the first thickness, and

a distance from the second zone to the optical center of the central zone is selected to generate pincushion distortion or barrel distortion in the eye of the patient.

2. The spectacle lens of claim 1 , wherein the second zone comprises at least one of:

a raised area on an anterior surface of the spectacle lens; a

raised area on a posterior surface of the spectacle lens;

a depressed area on an anterior surface of the spectacle lens; or a depressed area on a posterior surface of the spectacle lens.

3. The spectacle lens of claim 1 , wherein:

the second thickness is selected to generate peripheral defocus in the eye of the patient.

4. The spectacle lens of claim 1 , wherein:

the central zone includes a conic-section curve configured to generate a spherical aberration in the eye of the patient.

5. The spectacle lens of claim 4 , wherein:

the spherical aberration generated in the eye of the patient is one of a positive, negative or neutral spherical aberration.

6. The spectacle lens of claim 1 , wherein:

the second thickness in the second zone is selected to generate a different peripheral defocus in the eye of the patient in two or more semi-meridians.

7. The spectacle lens of claim 1 , wherein:

the distance of the second zone to the center of the central zone is selected to generate different amounts of pincushion distortion or barrel distortion in the eye of the patient in two or more semi-meridians.

8. The spectacle lens of claim 1 , wherein:

the spectacle lens has a colorant added to the material or surface of the film to alter the spectral transmission of the spectacle lens.

9. The spectacle lens of claim 1 , wherein:

light sources are housed within the spectacle lens or on the surface of the spectacle lens for directing wavelength specific light into the eye of the patient.

10. A method for defining a spectacle lens to be manufactured for an eye of a patient, comprising:

selecting a central zone having an optical center corresponding to the visual axis of an eye of the patient; and

selecting a peripheral zone peripheral to the central zone; and selecting, for the peripheral zone:

a first zone having a first thickness, and

a second zone having a second thickness, wherein:

the second thickness varies from the first thickness, and

a distance from the second zone to the optical center of the central zone is selected to generate pincushion distortion or barrel distortion in the eye of the patient.

11. The method of claim 10 , further comprising:

selecting, for the second zone, at least one of:

a raised area on an anterior surface of the spectacle lens; a raised area on a posterior surface of the spectacle lens;

a depressed area on an anterior surface of the spectacle lens; or a depressed area on a posterior surface of the spectacle lens.

12. The method of claim 10 , further comprising:

selecting the second thickness to generate peripheral defocus in the eye of the patient.

13. The method of claim 10 , further comprising:

selecting, for the central zone, a conic-section curve to generate a spherical aberration in the eye of the patient.

14. The method of claim 13 , wherein:

the spherical aberration generated in the eye of the patient is one of a positive, negative or neutral spherical aberration.

15. The method of claim 10 , further comprising:

selecting the second thickness in the second zone to generate a different peripheral defocus in the eye of the patient in two or more semi-meridians.

16. The method of claim 10 , further comprising:

selecting the distance of the second zone to the center of the central zone to generate different amounts of pincushion distortion or barrel distortion in the eye of the patient in two or more semi-meridians.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2024
From: LIU, GAOZHI
To: SHENYANG KANGENDE MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.
Reel/Frame 067345/0442 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2024
From: LEGERTON, JEROME A.; LIU, JIDONG
To: SHENYANG KANGENDE MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.
Reel/Frame 067340/0348 →
Continuity (3)
Continuation 18217953 · Jul 3, 2023
Continuation 17795531
Related Publication 20240329431A1 · Oct 3, 2024
References Cited (46)
US 3195145A · Tisher et al. · 1965 [cited by applicant]
US 3904281A · Jampolsky · 1975 [cited by applicant]
US 4645317A · Frieder et al. · 1987 [cited by applicant]
US 5478824A · Burns et al. · 1995 [cited by applicant]
US 5793467A · Bailey · 1998 [cited by applicant]
US 6027214A · Graham · 2000 [cited by applicant]
US 6170952B1 · La Haye et al. · 2001 [cited by applicant]
US 6488374B1 · Alberts · 2002 [cited by applicant]
US 6533418B1 · Izumitani et al. · 2003 [cited by applicant]
US 6736506B2 · Izumitani et al. · 2004 [cited by applicant]
US 7036929B1 · Harvey · 2006 [cited by applicant]
US 10571717B2 · Neitz et al. · 2020 [cited by applicant]
US 10921612B2 · Zhou et al. · 2021 [cited by applicant]
US 11061253B2 · Back et al. · 2021 [cited by applicant]
US 20010022649A1 · Fukuma et al. · 2001 [cited by applicant]
US 20030090625A1 · Izumitani et al. · 2003 [cited by applicant]
US 20040085516A1 · Fukuma et al. · 2004 [cited by applicant]
US 20050068489A1 · Hall et al. · 2005 [cited by applicant]
US 20060232743A1 · Legerton · 2006 [cited by applicant]
US 20140293216A1 · Muradore · 2014 [cited by examiner]
US 20150219924A1 · Moine · 2015 [cited by examiner]
US 20160054587A1 · Brennan · 2016 [cited by examiner]
US 20160178934A1 · Curley et al. · 2016 [cited by applicant]
US 20170059885A1 · Patel · 2017 [cited by applicant]
US 20170184875A1 · Newman · 2017 [cited by applicant]
US 20170269379A1 · Arieli et al. · 2017 [cited by applicant]
US 20170276961A1 · Wooley · 2017 [cited by examiner]
US 20180157065A1 · Curley et al. · 2018 [cited by applicant]
US 20180243082A1 · Zheleznyak et al. · 2018 [cited by applicant]
US 20190033619A1 · Neitz et al. · 2019 [cited by applicant]
US 20190302481A1 · Zhou et al. · 2019 [cited by applicant]
US 20200330218A1 · Canovas Vidal · 2020 [cited by examiner]
US 20210055573A1 · Back et al. · 2021 [cited by applicant]
US 20210191155A1 · Brennan · 2021 [cited by examiner]
US 20210271111A1 · Calvin · 2021 [cited by applicant]
US 20220329933A1 · Zhao · 2022 [cited by examiner]
CA 2685355A1 · 2008 [cited by applicant]
CN 212234798U · 2020 [cited by applicant]
CN 212466322U · 2021 [cited by applicant]
JP 2010507833A · 2010 [cited by applicant]
TW 201120500A · 2011 [cited by applicant]
TW 201421105A · 2014 [cited by applicant]
PCT International Search Report and Written Opinion mailed Mar. 28, 2022, issued in related International Application No. PCT/CN2021/104970 (8 pages). [cited by applicant]
Notice of Allowance mailed May 22, 2023, issued in related U.S. Appl. No. 17/795,531 (11 pages). [cited by applicant]
First Search dated Jul. 13, 2023, issued in related Chinese Application No. 202180008766.2 (2 pages). [cited by applicant]
Notice of Allowance mailed Apr. 11, 2024, issued in related U.S. Appl. No. 18/217,953 (12 pages). [cited by applicant]